Teva Pharmaceuticals Recalls Generic Parkinson’s Disease Based on Danger of Being “Superpotent”
On August 28, 2014, Teva Pharmaceuticals voluntarily recalled a batch of its generic Parkinson’s disease combination medication, Carbidopa/Levodopa (25 mg/100 mg), in the United States based on concerns that the medicine contained too much of the active ingredient. The Class II Recall involves 3,881 bottles of the medication Carbidopa/Levodopa (25 mg/100 mg).
The Recall Notice issued by Teva explains that the reason for the recall is due to the potential for “superpotent” tablets of carbidopa/levodopa (25 mg/100 mg). The Recall Number is D-1538-2014 and the particular lot affected is 29C220 (Exp. 11/15) according to the notice.
The choice of a lawyer is an important decision and should not be based solely on advertisements.